| gap-pubmed-20260411- | How do CHCHD10 mutations cause mitochondrial dysfunction leading to FTD-ALS path | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms link CHCHD10 mutations to the specific phenotype of ea | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the direct molecular targets of ginsenoside Rk1 that initiate its neuro | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does ginsenoside Rk1 modulation of PI3K/Akt pathway lead to increased synapt | open | 0.83 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | How does ferroptosis induction by ailanthone connect to the HIF-1α/LINC01956 pat | open | 0.71 | 0.00 | 2026-04-11 | 0 | | neuro-oncology |
| gap-pubmed-20260411- | What determines the specificity of LINC01956-FUS interaction versus other RNA-bi | open | 0.74 | 0.00 | 2026-04-11 | 0 | | molecular-neurobiology |
| gap-pubmed-20260411- | How does ailanthone selectively cross the blood-brain barrier and target glioma | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuro-oncology |
| gap-pubmed-20260411- | What determines tissue-specific sensitivity to FIR-mediated TRPV3 activation in | open | 0.76 | 0.00 | 2026-04-11 | 0 | | ischemiareperfusion |
| gap-pubmed-20260411- | How does FIR irradiation specifically upregulate TRPV3 expression at the molecul | open | 0.79 | 0.00 | 2026-04-11 | 0 | | cellular-signaling |
| gap-pubmed-20260411- | What determines the specificity of LGALS3-mediated MGnD-astrocyte cross-talk for | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does APOE4 specifically activate the ITGB8-TGFβ pathway in microglia? | resolved | 0.83 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What mechanisms underlie the sex-dependent differences in APOE4's effects on MGn | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What is the functional role of BACE2 and how does it differ from BACE1 in substr | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the physiological functions of BACE1 beyond APP processing that could c | partially_addressed | 0.89 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do ASOs show variable efficacy across different polyQ disorders despite shar | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines ASO selectivity for mutant versus wild-type alleles in polyQ dis | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do genetic and environmental factors interact with immune responses to trigg | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific pathogenic mechanisms by which immune system dysfunction d | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How should GBA-PD patients be stratified for clinical trials to optimize therape | resolved | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What specific pathological mechanisms link GBA mutation severity to distinct PD | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines cordycepin's differential effects on ERK/JNK versus other MAPK f | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does cordycepin simultaneously inhibit PI3K/AKT/mTOR while promoting autopha | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Do the iron-responsive transcriptomic changes in microglia causally drive PD pat | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What specific microglial factors mediate iron-induced neurotoxicity in the tri-c | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does SEC24B mechanistically regulate microglial ferroptosis and iron homeost | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines tissue-specific efficacy of PGRN elevation in myeloid versus neu | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does latozinemab selectively decrease sortilin levels without affecting othe | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Does TopIIbeta function cell-autonomously in neurons or require non-neuronal cel | open | 0.77 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What is the molecular mechanism by which TopIIbeta regulates neurite outgrowth a | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodevelopment |
| gap-pubmed-20260411- | Why does neurogenesis decline selectively in anterior-mid but not posterior dent | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroanatomy |
| gap-pubmed-20260411- | What mechanisms maintain neurogenesis despite reduced angiogenesis and smaller p | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurogenesis |
| gap-pubmed-20260411- | Why does human hippocampal neurogenesis persist with aging while it declines in | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurogenesis |
| gap-pubmed-20260411- | Why does p62 persist after stress granule and TDP-43 aggregate clearance during | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms drive the transition from stress granules to pathologi | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do ALS fibroblasts show genotype-specific stress responses while iPSC-motone | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines whether stress granules remain transient versus becoming persist | resolved | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do RNA recognition motifs regulate LLPS assembly in the presence of differen | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms drive the transition from reversible LLPS droplets to | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does H63D HFE variant frequency correlate with Parkinson's disease progressi | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms link H63D HFE variant to REDD1 upregulation and mTORC1 | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does iron chelation therapy worsen outcomes in H63D HFE variant carriers des | partially_addressed | 0.89 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does USP33 inhibition translate to neuroprotection in vivo and across differ | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines USP33's substrate specificity for different ubiquitin linkage ty | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does USP33 preferentially increase K63-linked over K48-linked PRKN ubiquitin | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the optimal timing and dosing strategy for BMT in progranulin-deficient | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does progranulin reconstitution only partially reverse neuroinflammation des | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms enable bone marrow-derived cells to cross the blood-brain barrie | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does amyloid deposition alter the therapeutic response to RXR agonists at di | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the direct molecular targets through which bexarotene reverses Aβ42-ind | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does APOE isoform mechanistically control RXR cistrome binding patterns and | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |